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Introduction: Neuroepithelial Transforming Gene 1 (NET1) is a well characterised oncoprotein and a proven marker of
an aggressive phenotype in a number of cancers, including gastric adenocarcinoma. We aimed to investigate whether
NET1 plays a functional role in oesophageal cancer (OAC) and its pre-malignant phenotype Barrett’s oesophagus.
Methods: Baseline NET1 mRNA levels were determined by qPCR across a panel of six cell lines, including normal
oesophageal, Barrett’s and OAC derived cells. Quantification of NET1 protein in OAC cells was performed using Western
blot and immunofluorescence. NET1 expression was modulated by treating with lysophosphatidic acid (LPA) and
NET1-specific siRNA. The functional effects of NET1 knockdown were assessed in vitro using proliferation, migration and
invasion assays.
Results: NET1 expression was increased in Barrett’s and in OAC-derived cells in comparison to normal oesophageal
cells. The highest expression was observed in OE33 a Barrett’s-related OAC cell line. NET1 protein and mRNA expression
was enhanced by LPA treatment in OAC and furthermore LPA treatment caused increased proliferation, migration and
invasion in a NET1-dependent manner. NET1 knockdown resulted in reduced OAC cell proliferation and invasion.
Conclusions: As found in other malignancies, NET1 expression is elevated in OAC and its pre-malignant phenotype,
Barrett’s oesophagus. NET1 promotes OAC cell invasion and proliferation and it mediates LPA-induced OAC cell migration.
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Gastrointestinal oncologyIntroduction
Cancer of the oesophagus consists of two major histological
subtypes - squamous cell carcinoma and adenocarcinoma.
These clinically, biologically and morphologically distinct
cancers, display different epidemiology and mandate differ-
ent clinical approaches to their management. Adenocar-
cinoma occurs in the lower third of the oesophagus and
oesophago-gastric junction and shares much in terms of
phenotype with gastric cancer. Similar to gastric cancer,
intestinal metaplasia can be a prominent precursor lesion
in adenocarcinoma of the oesophagus [1,2]. This condi-
tion is known as Barrett’s oesophagus. Barrett’s can repre-
sent a pre-malignant stage for oesophageal cancer and can* Correspondence: conorlahiff@physicians.ie
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reproduction in any medium, provided the ormanifest as low risk (non dysplastic) lesions or higher risk
lesions showing dysplasia histologically which can be low
or high grade. Oesophageal cancer (OAC) usually pre-
sents late with symptoms such as dysphagia, weight loss,
substernal pain or pressure or systemic symptoms and
this is reflected by poor 5 year survival figures (less than
10% for patients with advanced disease [3]).
Neuroepithelial Transforming Gene 1 (NET1) is a guan-
ine nucleotide exchange factor (GEF) which acts via activat-
ing RhoA [4]. Rho proteins belong to the Ras superfamily
of GTPases and are involved in regulating the actin cyto-
skeleton, signal transduction and gene transcription. These
molecules bring about their downstream effects by their
GTPase activity, shuttling between an inactive GDP-bound
and an active GTP-bound state. This cyclical activation/
inactivation brings about a conformational change withtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of cellular processes, including cell motility [5]. Rho
activation occurs in response to many cellular stimuli,
including lysophosphatidic acid (LPA). LPA is a bio-
active phospholipid and potent signalling molecule which
acts through a family of G protein coupled receptors [6].
It induces cellular proliferation through its receptors and
activation of Rho. In our previous studies LPA activation
of RhoA was shown to be mediated via NET1 in gastric
cancer [4]. NET1 is involved in cytoskeletal organisation
and cancer cell invasion [7-10]. Initially identified in a
neuroepithelioma cell line, it is tumorigenic in nude
mice [11]. In vitro studies have shown NET1 expression
to drive invasion in gastric adenocarcinoma [12]. Separ-
ately it has also been shown to be functionally important
in epithelial mesenchymal transition in retinal epithelial
cells [13], keratinocytes [14] and during gastrulation [15].
NET1 has previously been shown to be differentially
expressed and functionally important in mediating can-
cer cell invasion in gastric cancer [12,16] and in squa-
mous cell skin cancer (17). It has also been shown to be
prominent in a number of other cancers [17-21] and to be
a marker of poor prognosis in many of these (Table 1).
Our group have previously shown NET1 to be of func-
tional importance in breast and gastric cancer [4,12,16,22].
Recognising the mounting cellular and molecular evi-
dence for a role for NET1 in mediating gastrointestinal
(GI) cancers and coupled with the phenotypic similar-
ities recognised in the pathogenesis of gastric and
oesophageal adenocarcinomas [1], we sought to investi-




Our in vitro oesophageal cell line model consisted of six cell
lines: Het1a an SV40 immortalised normal oesophageal cell
line derived from a 25 year old male; two Barrett’s cell
lines QhTERT and GihTERT previously established by
hTERT immortalisation (American Type Culture Collec-
tion, Virginia, USA) that represent non-dysplastic and
high grade dysplastic Barrett’s epithelium respectively; and
three Barrett’s related oesophageal adenocarcinoma cellTable 1 A summary of current data on NET1 in other human
Cancer type Role o
Gastric adenocarcinoma Invasion
Breast cancer Predicts late stage
Mediates morphine-indu
Glioma Marker of invasion and aggressive di
Hepatocellular carcinoma Correlates with high
Cervical carcinoma Highly expressed in cervical epitlines - OE33, OE19 and JH-EsoAd1. OE33 was established
from an adenocarcinoma of the lower esophagus of a
73-year-old female patient and is pathological stage IIA
and poorly differentiated. OE19 is a pathological stage
III moderately differentiated adenocarcinoma of gastric
cardia/oesophageal gastric junction in a 72-year-old male
patient. JH-EsoAD1 is from a patient with Barrett’s associ-
ated adenocarcinoma [23]. AGS is a gastric cancer cell line
from a 54 year old female and represents a moderate to
poorly differentiated adenocarcinoma. SW480 is from a
locally invasive (Duke’s stage B) colon adenocarcinoma.
QhTERT, GihTERT, OE33, OE19, Jh-EsoAd1, AGS and
SW480 cells were cultured in RPMI 1640 medium
containing 10% fetal calf serum, 2 mM Glutamine and
penicillin/streptomycin. Cells were cultured in T-75 flasks
maintained at 37°C in a humidified atmosphere of 5%
CO2. Het1a required a supporting layer composed of
extracellular matrix proteins for subculture. Flasks
were coated with 0.01 mg/ml bovine serum albumin,
0.01 mg/ml fibronectin and 0.03 mg/ml bovine type I
collagen and were incubated overnight at 37°C in 5%
CO2. Het1a was cultured in BEBM medium containing
BPE 0.4%, insulin 0.5 ml, hydrocortisone 0.5 ml, gentamicin/
amphotericin 0.5 ml, retinoic acid 0.5 ml, transferring
0.5 ml, triiodothyronine 0.5 ml, epinephrine 0.5 ml and
hEGF 0.5 ml (Lonza Clonetics, Walkersville, USA). Flasks
were maintained at 37°C in a humidified atmosphere
of 5% CO2.RNA extraction and qPCR
RNA extraction was carried out using TRIzol™ reagent
(Sigma Aldrich, Ireland) under standard conditions. Quan-
titative PCR was carried out by the SyBr Green method
using the Rotor-Gene™ 3000A Real Time Thermal Cycler
and the Rotor-Gene™ 6 software package. Specifically de-
signed primers for NET-1 were purchased from Qiagen
(Crawley, West Sussex, UK) and GAPDH was used as an
endogenous control.Western blot
Following LPA stimulation or siRNA treatment, cells were
lysed and total protein was analysed by immublot usingcancers
f NET1 Reference
via RhoA Leyden et al. [12]
Murray et al. [4]
and poor prognosis Gilcrease et al. [18]
ced cell migration in vitro Ecimovic et al. [22]
sease. Poorer survival in NET1 positive Tu et al. [20]
er histological grade Chen et al. [17]
helial neoplasia and in carcinoma Wollscheid et al. [21]
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IgG monoclonal antibody.
Immuno-fluorescence
2 × 104 cells were seeded into 8 well chamber slides,
treated with either NET-1 specific siRNA or scramble
siRNA and incubated at 37°C for 24 hours with 5% CO2.
Immuno-fluorescence was measured using SC-81333
(Santa Cruz, United States) NET1 specific mouse IgG
monoclonal antibody and a FITC labelled secondary
antibody.
Optimisation of LPA treatment by dose/response
In order to determine optimal treatment conditions for
LPA in OE33 and het1a cell lines a dose/response ex-
periment was performed. Cells were treated with 1, 5, 10
and 20 μl LPA and. NET1 mRNA expression was quan-
tified by qPCR and protein expression was examined by
Western blot.
Gene knockdown by siRNA
Two siRNA duplexes were designed and synthesised for
silencing NET1 (Qiagen Inc. CA, USA). The duplexes
were termed: NET1-1 (sense, 5′- GGA GGA UGC UAU
AUU GAU A-3′; antisense, 5′- UAU CAA UAU AGC
AUC CUC C-3′) and NET1-2 (sense, 5′- GGU GUG
GAU UGA UUG GAA A- 3′; antisense, 5′ UUU CCA
AUC AAU CCA CAC C-3′). A chemically synthesized
non-silencing siRNA duplex (sense, 5′-UUC UCC GAA
CGU GUC ACG U-3′; antisense, 5′-ACG UGA CAC
GUU CGG AGA A-3′) that had no known homology
with any mammalian gene was used to control for non-
specific silencing events. 4 × 105 OE33 cells were added
to each well of a 6-well plate containing 2 ml growth
media and were incubated under the standard conditions
of 37°C and 5% CO2 in a humid incubator for 24 hr. After
24 hrs the siRNA-containing culture medium was aspi-
rated and 1.9 ml of new medium was added to each well.
1 μl (0.3 μg, 10nM), 5 μl (1.5 μg, 50nM), 17 μl (5 μg,
170nM) and 25 μl (7.5 μg, 250nM) siRNA were added to
serum-free RPMI medium and then diluted appropri-
ately in serum-containing medium as per manufacturer’s
instructions. Each specific oligonucleotide (NET1-1 and
NET1-2) was examined individually and together in the
same solution. NET1 mRNA expression was quantified by
qPCR and protein expression was examined by Western
blot and immunofluorescence.
Proliferation assay
20 μl of MTS reagent was added to each well of a 96
well plate containing 2 × 104 cells. Treatments were as
follows; 10nM scramble siRNA (control), 10nM NET1-1
siRNA, 10nM scramble siRNA + 5 μM LPA and 10nM
NET1-1 + 5 μM LPA. After transfection with siRNA, cellswere incubated for 24 hours. MTS was then added and
the plate was incubated for 2 hours at 37°C and 5% CO2
and absorbance at 492 nm was read using a microplate
reader.
Migration assay
Wound healing migration assays were performed using
plastic well inserts (Ibidi, Germany) in 24 well plates.
8 × 104 cells were seeded to each side of a plastic insert
inside each well. The following day 10nM NET1-1 siRNA
was added with 10nM scramble siRNA acting as a con-
trol. Cells were incubated under standard conditions for
24 hours to achieve knockdown of NET1. Inserts were
then carefully removed from each well and cells were
fed with regular growth medium without siRNA. Wells
for LPA treatment were treated with 5 μM in medium.
Cells were observed until they had migrated but not
long enough to allow full closure of the gap created by
removal of the insert (3 hours). Cells were then fixed
using 1:1 methanol acetone and stained with crystal vio-
let. Each well was then photographed at 3 hours and
measurements were taken for each condition at three
points along the gap between mono-layers of cells. All
treatment conditions were carried out in triplicate and
averages were calculated and recorded as distance in
number of pixels across the gap. Comparisons were made
between the scramble siRNA and NET1 knockdown wells.
Analysis calculated average migration distances using
Image J software (http://rsb.info.nih.gov/ij/).
In vitro invasion assay
Biocoat Matrigel (BD Biosciences, United Kingdom) inva-
sion chambers were used to investigate and compare the
effect of NET1 downregulation on the in vitro invasion of
OE33 cells. 1 × 105 cells were seeded to the upper cham-
ber in serum-free medium. Culture medium containing
20% FBS was added to the outer chambers which acted as
a chemo-attractant for the cells. The plates were then in-
cubated for 24 hr in a 5% CO2 humidified 37°C incubator.
Following incubation, the cells which had invaded the
membrane were fixed and stained. The membrane was
then removed and mounted on a slide for microscopic as-
sessment. Invasive cells were visualised at 40X magnifica-
tion and the number of cells in five random fields were
counted and an average calculated for each condition.
Statistics
All experiments were carried out in triplicate unless other-
wise stated in results section. Quantitative PCR analysis
was by delta Ct method and GAPDH was used to normal-
ise the data. Bivariate statistical analysis was carried out
using the student’s t-test with the level of statistical signifi-
cance taken as p < 0.05.
Table 2 NET-1 mRNA expression in Barrett’s oesophagus and oesophageal cancer cell lines relative to het1a (normal)
oesophageal cell line
Cell line Description Mean NET1 expression Standard deviation
Het1a Normal oesophagus 1.0 0
QhTERT Non-dysplastic Barretts epithelium 54.8 65.5
GihTERT High grade dysplastic Barretts epithelium 2.8 2.5
JH-EsoAd1 C 2.8 2.5
OE19 OAC 61.5 30.3
OE33 Stage IIa, poorly differentiated OAC 180.4 178.4
Specific cell lines are as identified in methods section.
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NET1 Expression is upregulated in oesophageal cancer cells
Relative NET1 mRNA expression across all six cell lines
is shown in Table 2. Het1a (normal) cell line set at an ar-
bitrary reference value of 1. There is a marked higher
level of expression in the OE33 cell line. Because of this
high NET1 level we chose this cell line for further experi-
ments to characterise the role of NET1 in oesophageal can-
cer. Looking at other in vitro GI cancer models (Additional
file 1: Figure S1), the OE33 cell line had greater NET1Figure 1 NET1 expression following knockdown by siRNA in OE33 cells
siRNA oligonucleotide 1 (KD1), NET1 siRNA oligonucleotide (KD2) and both si
expression in OE33 cells after gene knockdown, using tubulin expression as a
control. C) Immunofluorescence images from OE33 cells after siRNA NET1 gen
compared to (scrambled) control siRNA at 24 hours incubation. Secondary anmRNA expression compared to gastric (AGS) and colo-
rectal (SW480) adenocarcinoma models.
NET1 MRNA expression is modulated by targeted siRNA
and LPA
Optimal NET1 gene knockdown conditions were deter-
mined by dose–response and time-course transfections in
OE33 cells. The most effective knockdown (76%) was ob-
served at 10nM for 24 hours using NET1 duplex 1, as
shown in Figure 1A (0.24 vs. control, p = 0.01). Similar. A) NET1 mRNA expression after gene knockdown with NET1-specific
RNA in combination (KD 1&2). B) Western blot showing NET1 protein
control. Reduced expression was seen in NET1 knockdown compared to
e knockdown. Reduced fluorescence was observed for NET1 knockdown
tibody control image is included for reference.
Figure 2 NET1 expression following stimulation with LPA in
OE33 cells. A) Effect of LPA stimulation on NET1 mRNA expression in
OE33 cells. The most pronounced effect was seen at 5 μM where a 1.6
fold rise was observed (p = 0.13). B) NET1 protein expression in OE33
cells after stimulation with LPA. Tubulin was used as a housekeeper.
Figure 3 OE33 cell proliferation measured after NET1 knockdown (KD)
cells. Statistically significant differences are shown in bold.
Lahiff et al. Journal of Experimental & Clinical Cancer Research 2013, 32:55 Page 5 of 9
http://www.jeccr.com/content/32/1/55effects on NET1 protein expression were shown by West-
ern blot and immunofluorescence (Figure 1B and C).
Maximum LPA effect (1.6 fold rise in NET1 mRNA,
p = 0.13) was seen at a treatment concentration of 5 μM
for 4 hours, as shown in Figure 2A. Consistent with this,
LPA treatment was shown to result in elevated Net1
protein levels (Figure 2B).
NET1 Knockdown reduces OAC cell proliferation
NET1 gene knockdown reduced OE33 cell proliferation
by 32% (mean absorbance 0.46 versus 0.68, p = 0.03) in
comparison to scramble siRNA control (Figure 3). Treat-
ment with LPA had no significant effect on OAC cell
proliferation. NET1 knockdown cells treated with LPA
showed significantly reduced proliferation (39% reduc-
tion, p = 0.01) compared to control cells treated with
LPA under the same conditions.
NET1 Mediates LPA induced migration in OAC cells
Figure 4 illustrates the effects of LPA treatment and NET1
knockdown on OAC cell migration, using gap width at
time 0 as a reference. A higher level of migration was ob-
served in LPA treated cells compared to non-targeting
(NT) siRNA (control) cells (383.3 mean pixels versus
318.1 or 20% increase in migration, p = 0.01). NET1 gene
knockdown (KD) resulted in 25% reduction in migration
(240 mean pixels versus 318.1, p = 0.03). NET1 knock-
down cells treated with LPA had a 22% reduction in mi-
gration in comparison with control (NT + LPA), (298.5
versus 383.3 mean pixels, p = 0.0003).and 5 μM LPA stimulation compared with control (scramble siRNA)
Figure 4 Trans-well migration of OE33 cells after NET1 gene knockdown (KD), 5μM LPA stimulation (NT+LPA) and both conditions
combined (KD+LPA). A) Migration across a gap is graphed by average number of pixels. Non-targeting siRNA (NT control) treated cells acted as a
sham control for gene knockdown and time=0 is included as a reference. Statistically significant differences are shown in bold. B) Light microcopy
images (10× magnification) of trans-well migration assay.
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NET1 knockdown cells were 45% less invasive at 24 hours
than control cells, as shown in Figure 5 (56.8 versus 102.6
mean cells per high power field, p = 0.04). Invasion was
increased by 78% in control cells after 5 μM LPA stimu-
lation compared with NET1 knockdown cells (117.1 vs
66.1 mean cells per high power field, p = 0.01).
Discussion
The biological events in OAC carcinogenesis and metas-
tasis are poorly understood. NET1 has been shown to be
functionally important as a mediator of invasion and
metastasis in gastric adenocarcinoma [12,16] and isprognostically significant in other epithelial cancers
[18,20]. We have demonstrated very high levels of NET1
expression in OAC and this strengthens our central hy-
pothesis that this well characterised oncoprotein may be
an important player in the molecular events leading to
neoplastic progression in Barrett’s and OAC. Analysis of
baseline NET1 expression levels in our in vitro oesophageal
model showed a progressive rise in expression from normal
oesophagus to Barrett’s to Barrett’s related OAC. The
higher expression of NET1 in OE33 OAC cells compared
with the other two OAC cell lines may be a reflection of
the poor level of differentiation these cells represent,
and it has been shown elsewhere that NET1 is seen at
Figure 5 Trans-membrane invasion of OE33 cells after NET1 knockdown (KD) and 5 μM LPA stimulation (control + LPA) over 24 hours
compared with control (NT/scramble siRNA). The final column represents both conditions combined (KD + LPA). Statistically significant
differences are shown in bold.
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[17,20]. In a recent study (Lahiff et al 2013, under review
British Journal of Cancer; Lahiff, et al. Gut 2012; 61:
(Suppl 2) A255 (abstract); and Lahiff et al. Gastroenter-
ology 2012; 142:5 (Suppl 1) S-531 (abstract)].) we have
analysed the levels of NET1 mRNA in OAC tumor tissue.
We showed that type I (Siewert classification) oesophago-
gastric junction (OGJ) adenocarcinomas expressed signifi-
cantly higher levels of NET1, with lowest expression in
type III and intermediate levels in type II (p = 0.01). In
patients with gastric and OGJ type III tumours, NET1
positive patients were more likely have advanced stage
cancer (p = 0.03), had a higher number of transmural
cancers (p = 0.006) and had a significantly higher me-
dian number of positive lymph nodes (p = 0.03). In this
subgroup, NET1 was associated with worse median
overall (23 versus 15 months, p = 0.02) and disease free
(36% versus 11%, p = 0.02) survival.
In the current study, we investigated the role of NET1
in OAC by modulating its expression and investigating
the effect on cell function. LPA stimulates invasion and
migration in OE33 cells. We have previously shown that
LPA, a phospholipid which acts through G protein coupled
receptors and is known to activate RhoA, promotes gastric
cancer cell invasion via NET1 [4]. In this current study we
have shown that not only does LPA drive NET1 expres-
sion in OAC but that the functional effects of LPA stimu-
lation in these cells are NET1 dependent. Although not
explored in the current study, our ongoing efforts willdefine whether LPA drives RhoA activation in OAC cells
as it does in gastric cancer cells. The mechanism by which
LPA induces transcription of NET1 in OAC cells remains
to be elucidated. We also previously reported LPA to drive
the expression of NET1 mRNA in gastric cancer cells [4].
Likewise, we previous showed [16] that stimulation of
gastric cancer cells with LPA resulted in the differential
expression of over 2000 genes. Further work will eluci-
date the mechanism via which LPA induces NET1 mRNA
transcription in OAC cells.
The results of the functional in vitro experiments
presented here are broadly consistent across prolifera-
tion, migration and trans-membrane invasion assays. NET1
knockdown significantly reduced OE33 cancer cell prolifer-
ation, migration and invasion. LPA, a recognised mitogen,
had no effect on proliferation in these OAC cells. However,
when we examine the effect of LPA on scramble siRNA
control cells compared with its effect after NET1 knock-
down there was significant differences in proliferation,
migration and invasion. While these results suggest the
effect of LPA in promoting proliferation, migration and
invasion in OAC may be NET1 dependent this needs to
be qualified by the fact that in control cells at baseline
we only observed a significant effect after LPA treat-
ments in the migration assay. Furthermore, although
not performed in this study, it would also be valuable to
monitor the effect of NET1 overexpression in OAC cells
and efforts, aimed at performing these analyses are cur-
rently ongoing.
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role in the metastasis of epithelial cancers through the
involvement of various intracellular signalling pathways
[24-26]. Loss of E-Cadherin is associated with EMT and
tumour invasion [27] and has been linked functionally
to NET1 and TGFβ [14]. Oesophageal cancer frequently
exhibits loss of E cadherin and TGFβ receptors [28].
Interestingly RhoA, which our group have previously
shown to be regulated by NET1 in gastric cancer [4],
has also been shown to activate TGFβ [29]. Further-
more, we have previously shown NET1 expression to be
required for the expression of TGFβi, a key member of
the TGF signalling pathway [16]. TGFβ is known to in-
duce NET1 expression and in turn RhoA activation and
reorganisation of the cytoskeletal via the Smad3 tran-
scription factor [13]. The putative role of NET1 in epi-
thelial mesenchymal transition via TGF-β [13,14,19,30]
and the significance of this concept in OAC, coupled
with the data presented here, strengthen the hypothesis
that NET1 plays an important role in the tumour biol-
ogy of oesophageal adenocarcinoma.
Conclusions
The data presented from this study demonstrates that
NET1, a recognised pro-invasive oncoprotein associated
with aggressive gastrointestinal and non-gastrointestinal
cancers is highly expressed and functionally active in OAC.
In aggregate our data provides strong evidence that NET1
is biologically active in OAC and may be an important fac-
tor in promoting an aggressive tumour cell phenotype.
Additional file
Additional file 1: Figure S1. NET1 mRNA expression in other in vitro GI
cancer models. OE33 cells line had highest expression of NET1 mRNA
expression compared to gastric (AGS) and colorectal (SW480)
adenocarcinoma models.
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